Biotech News

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB)Connect Biopharma Holdings LimitedEarnings

– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –

Related news

Connect Biopharma Holdings Limited

Connect Biopharma is an immunology company focused on inflammatory and autoimmune diseases. Its story is built around developing targeted therapies for chronic immune-mediated conditions.

Recent company news

Stock data

Close
0.63 USD
Market cap
135.37M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States